Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Compumedics Ltd

Healthcare AU CMP

0.265AUD
0.00(0%)

Last update at 2026-06-03T02:57:00Z

Day Range

0.260.27
LowHigh

52 Week Range

0.240.45
LowHigh

Fundamentals

  • Previous Close 0.27
  • Market Cap54.93M
  • Volume50935
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3.52M
  • Revenue TTM58.49M
  • Revenue Per Share TTM0.26
  • Gross Profit TTM 31.24M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.59300M 0.48M -6.71900M 1.70M 0.78M
Minority interest - - - - -
Net income -1.27200M -0.33800M -6.12200M 1.36M 1.00M
Selling general administrative 17.39M 7.08M 6.41M 5.64M 6.12M
Selling and marketing expenses 11.74M 14.06M 13.25M 9.48M 8.26M
Gross profit 30.99M 26.07M 21.59M 19.29M 19.16M
Reconciled depreciation - 1.57M 1.01M 1.21M 1.46M
Ebit 0.71M 1.22M -2.97900M 2.10M -0.35100M
Ebitda 1.94M 2.79M -1.96600M 2.61M 1.11M
Depreciation and amortization 1.23M 1.57M 1.01M 0.51M 1.46M
Non operating income net other - - - - -
Operating income 0.71M -0.81200M -3.01900M 0.99M 0.96M
Other operating expenses 50.33M 50.53M -7.35400M 0.36M -1.47800M
Interest expense 1.28M 0.74M 0.65M 0.40M 0.33M
Tax provision 0.86M 0.82M -0.59700M 0.34M -0.22200M
Interest income 1.31M 0.92M 0.61M 0.23M 1.14M
Net interest income - -0.73900M -0.65200M -0.40100M -0.33000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.68M 0.82M -0.59700M 0.34M -0.22200M
Total revenue 51.04M 49.72M 42.41M 37.76M 35.74M
Total operating expenses 30.27M 26.88M 26.14M 19.69M 18.76M
Cost of revenue 20.05M 23.65M 20.82M 18.46M 16.58M
Total other income expense net -1.30700M 1.29M -2.53300M 1.99M 0.71M
Discontinued operations - - - - -
Net income from continuing ops - -0.33800M -6.12200M 1.36M 1.00M
Net income applicable to common shares -1.26800M -0.33800M -6.12200M 1.36M 1.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 54.39M 40.15M 41.18M 41.49M 38.55M
Intangible assets 16.59M - 6.24M 6.45M 4.08M
Earning assets - - - - -
Other current assets 2.99M 0.71M 2.43M 2.35M 2.47M
Total liab 32.57M 22.13M 22.89M 17.90M 16.39M
Total stockholder equity 21.82M 18.02M 18.29M 23.59M 22.16M
Deferred long term liab - - 6.24M 6.45M 4.08M
Other current liab 6.74M 4.46M 4.26M 3.51M 3.15M
Common stock 39.45M 35.65M 35.65M 35.65M 35.65M
Capital stock - - 35.65M 35.65M 35.65M
Retained earnings -18.58400M -17.47300M -17.79100M -11.66900M -13.02600M
Other liab - - 0.14M 0.20M 0.29M
Good will - - - - -
Other assets - - 1.10M 6.95M 4.90M
Cash 2.69M 1.89M 3.80M 7.08M 6.77M
Cash and equivalents - - - 7.08M -
Total current liabilities 32.11M 21.22M 21.19M 17.32M 15.35M
Current deferred revenue - 1.34M 2.69M 1.92M 1.75M
Net debt 11.19M 6.68M 5.67M -0.74700M -0.95000M
Short term debt 13.70M 7.72M 7.91M 5.95M 5.07M
Short long term debt - - 7.22M 5.80M 4.41M
Short long term debt total 13.88M 8.56M 9.47M 6.33M 5.82M
Other stockholder equity - -0.16500M -17.86300M -23.98500M -22.62800M
Property plant equipment - - 3.62M 1.21M 1.71M
Total current assets 35.22M 25.95M 29.52M 33.33M 31.93M
Long term investments - - 0.70M - -
Net tangible assets - - 18.29M 23.59M 22.16M
Short term investments - - - - -
Net receivables 14.88M 10.45M 12.53M 14.12M 13.01M
Long term debt - - 0.20M 0.38M 0.59M
Inventory 14.66M 12.91M 10.69M 9.71M 9.68M
Accounts payable 11.68M 7.70M 6.33M 5.94M 5.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.96M - 0.43M -0.39400M -0.47300M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M 10.16M - -1.21300M -1.71100M
Deferred long term asset charges - - - - -
Non current assets total 19.17M 14.20M 11.66M 8.16M 6.61M
Capital lease obligations - - 2.04M 0.15M 0.82M
Long term debt total - - 1.56M 0.38M 0.75M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -2.98700M -4.40800M -2.95900M -1.84300M
Change to liabilities - - 0.49M 0.92M 1.40M
Total cashflows from investing activities -7.37400M -2.98700M -4.40800M -2.95900M -1.55400M
Net borrowings - -0.94600M -1.00500M 1.28M -0.17900M
Total cash from financing activities 6.10M -1.49000M -1.00500M 1.28M -0.17900M
Change to operating activities - - 0.68M 0.52M -1.11800M
Net income -1.27200M -0.33800M -6.12200M 1.36M 1.00M
Change in cash -0.55600M -2.56900M -4.99400M 1.94M -0.87300M
Begin period cash flow -0.26900M 2.30M 7.29M 5.14M 6.01M
End period cash flow -0.82500M -0.26900M 2.30M 7.08M 5.14M
Total cash from operating activities 0.68M 2.00M 0.05M 3.29M 1.32M
Issuance of capital stock - - - - -
Depreciation 2.25M 1.57M 0.98M 1.13M 1.37M
Other cashflows from investing activities -7.16000M -2.67400M - - -
Dividends paid - - - - -
Change to inventory -1.44500M -2.52200M -0.98100M -0.03000M -0.84700M
Change to account receivables -6.73100M 3.82M 1.51M -0.98700M -0.41500M
Sale purchase of stock - - - - -
Other cashflows from financing activities 3.20M -0.54400M -0.14500M 3.83M -0.12100M
Change to netincome - - 3.37M 0.60M -0.04100M
Capital expenditures 0.21M 2.99M 4.41M 2.96M 1.84M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -7.69200M 1.55M 0.53M -1.01700M -1.26200M
Stock based compensation - - - - -
Other non cash items 7.40M -0.78000M 4.66M 1.81M 0.22M
Free cash flow 0.47M -0.98600M -4.35900M 0.33M -0.51900M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMP
Compumedics Ltd		 - -% 0.27 - 14.37 0.94 2.35 1.14 12.11
COH
Cochlear Ltd		 -1.64 1.70% 95.10 18.48 18.62 2.72 3.31 2.76 11.44
4DX
4DMEDICAL Ltd		 -0.06 1.56% 3.79 - - 340.72 37.59 355.67 -7.2899
AVR
Anteris Technologies Global Corp		 0.50 4.00% 13.00 - - 630.02 3.17 326.80 -5.1986
PNV
Polynovo Ltd		 -0.03 2.71% 1.07 125.50 40.49 6.22 10.01 5.96 119.61

Reports Covered

Stock Research & News

View All

Profile

Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in the Americas, Australia, the Asia Pacific, Europe, and the Middle East. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; and Somté, an investigative tool. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG, Grael 4K-EEG, and Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, a portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and source localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; Somte and Persyst Software; HD Digital Video; Profusion Plus; ECG Free software; and TCM5 FLEX Transcutaneous Monitor, Grael DC, Siesta extended battery pack, and Summit IP products. Further, the company offers magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. Additionally, the company provides doppler diagnostic products; Nuevo LTM EEG; Orion LifeSpan MEG; and quik-cap EEG electrode arrays. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.

Compumedics Ltd

30-40 Flockhart Street, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. David Burton Ph.D. Founder, Exec. Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Sec. & Exec. Director 1965
Mr. Warwick Freeman Chief Technology Officer NA
Mr. Christoph Witte Gen. Managing of Director DWL Compumedics Germany GmbH NA
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & Gen. Legal Attorney NA
Dr. Curtis Ponton Chief Scientist of Neuroscan & VP NA
Mr. Paul Spooner Bus. Director of EMEA NA
Dr. David Burton Ph.D. Founder, Executive Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Secretary & Executive Director 1965
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & General Legal Attorney NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.